Li G - Search Results

1

Improving Chuanxiong Rhizoma quality standards using an effect-constituent index based bioassay.

Li C, Liu Y, Cao B, Lin M, Wang S, Dong B, Zhang M, Li G. Li C, et al. Among authors: li g. J Pharm Biomed Anal. 2023 Sep 5;233:115455. doi: 10.1016/j.jpba.2023.115455. Epub 2023 May 13. J Pharm Biomed Anal. 2023. PMID: 37201235

2

Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry.

Chen W, Shi Y, Qi S, Zhou H, Li C, Jin D, Li G. Chen W, et al. Among authors: li c, li g. J Anal Methods Chem. 2019 Mar 4;2019:7574369. doi: 10.1155/2019/7574369. eCollection 2019. J Anal Methods Chem. 2019. PMID: 30949374 Free PMC article.

3

Spectrum-Effect Relationship between UPLC Fingerprints and Antilung Cancer Effect of Si Jun Zi Tang.

Zhou X, Li Y, Zhang M, Hao J, Gu Q, Liu H, Chen W, Shi Y, Dong B, Zhang Y, Li C, Li G. Zhou X, et al. Among authors: li c, li y, li g. Evid Based Complement Alternat Med. 2019 Sep 22;2019:7282681. doi: 10.1155/2019/7282681. eCollection 2019. Evid Based Complement Alternat Med. 2019. PMID: 31662780 Free PMC article.

4

Screening for Susceptibility-Related Factors and Biomarkers of Xianling Gubao Capsule-Induced Liver Injury.

Li CY, Niu M, Liu YL, Tang JF, Chen W, Qian G, Zhang MY, Shi YF, Lin JZ, Li XJ, Li RS, Xiao XH, Li GH, Wang JB. Li CY, et al. Among authors: li rs, li gh, li xj. Front Pharmacol. 2020 May 29;11:810. doi: 10.3389/fphar.2020.00810. eCollection 2020. Front Pharmacol. 2020. PMID: 32547402 Free PMC article.

5

Development of alternative splicing signature in lung squamous cell carcinoma.

Yan JQ, Liu M, Ma YL, Le KD, Dong B, Li GH. Yan JQ, et al. Med Oncol. 2021 Mar 27;38(5):49. doi: 10.1007/s12032-021-01490-1. Med Oncol. 2021. PMID: 33772655 Free PMC article.

6

Effect of Single-Dose and Short-Term Administration of Si Jun Zi Tang on the Pharmacokinetics of Gefitinib in Rats.

Li Y, Zhou X, Niu M, Zhang M, Gu Q, Chen W, Dong B, Zhang Y, Li R, Li C, Li G. Li Y, et al. Among authors: li c, li g, li r. Evid Based Complement Alternat Med. 2021 Jul 26;2021:6655449. doi: 10.1155/2021/6655449. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34354759 Free PMC article.

7

Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.

Yan JQ, Liu M, Ma YL, Le KD, Dong B, Li GH. Yan JQ, et al. Exp Biol Med (Maywood). 2022 Jun;247(11):910-920. doi: 10.1177/15353702221083254. Epub 2022 Mar 12. Exp Biol Med (Maywood). 2022. PMID: 35285286 Free PMC article.

8

Sphingolipid Metabolism and Signaling in Lung Cancer: A Potential Therapeutic Target.

Lin M, Li Y, Wang S, Cao B, Li C, Li G. Lin M, et al. Among authors: li c, li y, li g. J Oncol. 2022 Jun 28;2022:9099612. doi: 10.1155/2022/9099612. eCollection 2022. J Oncol. 2022. PMID: 35799611 Free PMC article. Review.

9

The roles of ubiquitin-proteasome system and regulator of G protein signaling 4 in behavioral sensitization induced by a single morphine exposure.

Wang Y, Hou X, Wei S, Yan J, Chen Z, Zhang M, Zhang Q, Lu Y, Zhang Q, Zheng T, Jia J, Dong B, Li Y, Zhang Y, Liang J, Li G. Wang Y, et al. Among authors: li y, li g. Brain Behav. 2023 Mar;13(3):e2922. doi: 10.1002/brb3.2922. Epub 2023 Feb 15. Brain Behav. 2023. PMID: 36793204 Free PMC article.

10

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy.

Xu J, Cao B, Li C, Li G. Xu J, et al. Among authors: li c, li g. Front Oncol. 2023 Jul 7;13:1218206. doi: 10.3389/fonc.2023.1218206. eCollection 2023. Front Oncol. 2023. PMID: 37483519 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49,619 results

Search Page

Filters